Publications by authors named "F Tahon"
Background: Non-ischemic cerebral enhancing (NICE) lesions following aneurysm endovascular therapy are exceptionally rare, with unknown longitudinal evolution.
Objective: To evaluate the radiological behavior of individual NICE lesions over time.
Methods: Patients included in a retrospective national multicentric inception cohort were analyzed.
Background: Neurointerventionists lack guidelines for the use of antithrombotic therapies in their clinical practice; consequently, there is likely to be significant heterogeneity in antithrombotic use between centers. Through a nationwide survey, we aimed to obtain an exhaustive cross-sectional overview of antithrombotic use in neurointerventional procedures in France.
Methods: In April 2021, French neurointerventional surgery centers were invited to participate in a nationwide 51-question survey disseminated through an active trainee-led research collaborative network (the JENI-RC).
Article Synopsis
- NICE lesions are rare complications that can happen after a procedure called aneurysm endovascular therapy (EVT) to treat bulging blood vessels in the brain.
- In a study of many patients, 31 people were found to have these lesions, most showing symptoms a month or so after the treatment.
- After follow-up, many patients either had no or very few lasting problems, but some still showed signs of the lesions on their brain scans even a long time later.
Objective: Intracranial aneurysm (IA) is a frequent vascular malformation that can be managed by endovascular treatment (EVT) or microsurgery. A previously treated IA can recanalize, which may require further treatment. The aim of our study was to evaluate procedural complications related to IA retreatment and their risk factors.
View Article and Find Full Text PDFBackground: Intracranial aneurysms (IAs) can be treated through endovascular treatment (EVT) or microsurgery (MS). Treated IAs can recanalize, which can lead to rupture or retreatment.
Objective: The aim of our study was to evaluate the natural history of previously treated IA, by evaluating the risk of rupture and the risk of retreatment.